医学
随机对照试验
不利影响
皱纹
面部修复
系统回顾
美容技术
梅德林
软组织
患者满意度
脂肪萎缩
外科
牙科
内科学
老年学
家庭医学
人类免疫缺陷病毒(HIV)
政治学
抗逆转录病毒疗法
病毒载量
法学
作者
Roberta Signori,Antony de Paula Barbosa,Fernando Cezar-dos-Santos,Ana Claudia Carbone,Silvio Ventura,Bryanne Brissian de Souza Nobre,Maria Luiza Boechat Borges Neves,Mariana Barbosa Câmara‐Souza,Rodrigo Lorenzi Poluha,Giancarlo De la Torre Canales
出处
期刊:Polymers
[MDPI AG]
日期:2024-09-11
卷期号:16 (18): 2564-2564
被引量:1
标识
DOI:10.3390/polym16182564
摘要
The primary objective of this systematic review study was to investigate the effectiveness, durability, and adverse events of PLLA treatment for aesthetic indications. The search strategy was performed in MEDLINE (Ovid). The electronic literature search of five databases was performed, from the inception of the databases until the 12th of February 2024. This was to identify randomized clinical trials that assessed PLLA treatment in adult individuals exhibiting facial aging and/or facial lipoatrophy. Risk of bias was assessed using the Cochrane Risk-of-Bias Tool for Randomized Trials (RoB 2). Eleven RCTs out of 1467 identified citations were included. Four studies showed increased dermal thickness, significant improvement in facial lipoatrophy severity and aesthetic clinical scores, after PLLA treatment with its effects sustained for at least 25 months. Two studies demonstrated the superiority of PLLA over injectable human collagen. Also, three studies showed positive results favoring PLLA when compared with PH gel in lipoatrophy severity, transepidermal water loss, skin quality, elasticity, and patient satisfaction. All adverse events were mild-to-moderate in intensity, and the main ones worth noting were bruising, hematoma, tenderness, nodules, and edema. Five out of eleven studies were considered having high risk of bias. The evidence on the effectiveness and safety of PLLA for facial rejuvenation is of low quality; thus, the reported high effectiveness, safety, and long-lasting effects for this purpose should be further investigated.
科研通智能强力驱动
Strongly Powered by AbleSci AI